The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- The Christie NHS Foundation Trust - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of The Christie NHS Foundation Trust human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The Christie NHS Foundation Trust with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the The Christie NHS Foundation Trust’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate The Christie NHS Foundation Trust’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of The Christie NHS Foundation Trust in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the The Christie NHS Foundation Trust’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with The Christie NHS Foundation Trust.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of The Christie NHS Foundation Trust and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
The Christie NHS Foundation Trust Snapshot 5
The Christie NHS Foundation Trust Overview 5
Key Information 5
Key Facts 5
The Christie NHS Foundation Trust - Research and Development Overview 6
Key Therapeutic Areas 6
The Christie NHS Foundation Trust - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
The Christie NHS Foundation Trust - Pipeline Products Glance 12
The Christie NHS Foundation Trust - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
The Christie NHS Foundation Trust Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
The Christie NHS Foundation Trust - Drug Profiles 14
cisplatin + etoposide 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Cisplatin + Etoposide + Radiation Therapy 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Epirubicin + Cisplatin + 5-Flourouracil 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Gemcitabine + Carboplatin 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Gemcitabine + Cisplatin 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Gemcitabine Hydrochloride 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Paclitaxel + Carboplatin 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Vincristine + Adriamycin + Cyclophosphamide 22
Product Description 22
Mechanism of Action 22
RandD Progress 23
Aldesleukin + Maxamine 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Bevacizumab 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Cetuximab + Radiation Therapy 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Irinotecan + 5-Fluorouracil + Radiation Therapy 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Mitomycin C + Capecitabine 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Temozolomide 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
The Christie NHS Foundation Trust - Pipeline Analysis 30
The Christie NHS Foundation Trust - Pipeline Products by Therapeutic Class 30
The Christie NHS Foundation Trust Pipeline Products By Target 32
The Christie NHS Foundation Trust - Pipeline Products by Route of Administration 34
The Christie NHS Foundation Trust - Pipeline Products by Molecule Type 35
The Christie NHS Foundation Trust - Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 38
Contact Us 38
Disclaimer 38List of Tables
The Christie NHS Foundation Trust - Pipeline by Therapy Area and Indication, 2010 8
The Christie NHS Foundation Trust - Pipeline by Stage of Development, 2010 9
The Christie NHS Foundation Trust - Monotherapy Products in Pipeline, 2010 10
The Christie NHS Foundation Trust - Combination Treatment Modalities in Pipeline, 2010 11
The Christie NHS Foundation Trust - Phase III, 2010 12
The Christie NHS Foundation Trust - Phase II, 2010 13
The Christie NHS Foundation Trust - Pipeline By Therapeutic Class, 2010 30
The Christie NHS Foundation Trust - Pipeline By Target, 2010 33
The Christie NHS Foundation Trust - Pipeline By Route of Administration, 2010 34
The Christie NHS Foundation Trust - Pipeline By Molecule Type, 2010 35

List of Figures
The Christie NHS Foundation Trust - Pipeline by Therapy Area and Indication, 2010 7
The Christie NHS Foundation Trust - Pipeline by Stage of Development, 2010 9
The Christie NHS Foundation Trust - Monotherapy Products in Pipeline, 2010 10
The Christie NHS Foundation Trust - Combination Treatment Modalities in Pipeline, 2010 11
The Christie NHS Foundation Trust - Pipeline By Therapeutic Class, 2010 30
The Christie NHS Foundation Trust - Pipeline By Target, 2010 32
The Christie NHS Foundation Trust - Pipeline By Route of Administration, 2010 34
The Christie NHS Foundation Trust - Pipeline By Molecule Type, 2010 35

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.